PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Dimetindene→

Dimetindene PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
5636-83-9
Molecular formula
C20H24N2
Molecular weight
292.4 g/mol
Drug class
First-generation antihistaminehistamine H1 receptor antagonist
Mechanism of action
Antagonises histamine H1 receptors, reducing histamine-mediated itching, vascular permeability and allergic symptoms. It can produce sedative effects, particularly with systemic formulations.
Indications / reported uses
  • Symptomatic relief of pruritus and allergic skin reactions with topical gel formulations
  • Symptomatic relief of allergic rhinitis, urticaria and other histamine-mediated symptoms with oral formulations in countries where authorised; route-specific indications are not interchangeable

Sources: NLM MeSH — Dimetindene · PubMed — Dimetindene H1 antihistamine · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Dimetindene PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dimetindene Permitted Daily Exposure (PDE) report (the Dimetindene PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dimetindene Occupational Exposure Limit (OEL) report (the Dimetindene OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.